Trending...
- UK Financial Ltd Confirms Official Corporate Structure of the Maya Preferred Project and Its Dual-Class Token System
- Daniel S. Romero, CFP® Earns Renowned Certification for Fiduciary Excellence
- California: Coho salmon are making a comeback in the Russian River for the first time in 30 years
SAN JOSE, Calif. - Californer -- Biomed Industries, Inc. (Biomed) announced today that it has developed a promising obesity drug, NA-921, which is poised for Phase 2/3 clinical trials. NA-921 is a small molecule drug available in oral formulation.
The Company is in discussions with potential partners for collaboration on a Phase 3 trial of NA-921, a promising candidate for treatment of diabetic obesity.
The drug is a once-a-day oral capsule based on a novel mechanism of action of GLP-1 and IGF-1 for which the Company has recently filed for patent protection. Its analogue/prodrug has already been approved by the FDA for a certain rare disease, for which the Company is in separate licensing discussions.
"We are actively seeking collaborators to work with us on this exciting new approach for the treatment of Diabetes and Obesity. NA-921 is novel in its approach to targeting both GLP-1 and IGF-1. The drug has shown only minor adverse events in a Phase 2A trial", said Dr, Lloyd Tran, Chairman and CEO of Biomed Industries. He continued "We believe that this new approach will provide a clear choice for patients wanting to have a much more convenient way to take an obesity drug as well as minimize side-effects they experience with current treatments."
More on The Californer
About Biomed Industries, Inc.
Biomed Industries™, Inc. is a pioneering bio-pharmaceutical enterprise dedicated to the innovation, development, and commercialization of groundbreaking drug therapeutics addressing unmet medical needs. Biomed stands at the forefront of discovery with its new portfolio of clinical stage drugs targeting Alzheimer's disease, MDD, Rett Syndrome, other neurological challenges, and now Diabetes/Obesity. Additionally, the company is venturing into harnessing AI for drug discovery, enhancing clinical trial procedures, and various other critical domains within the pharmaceutical and medical device sectors.
For further details, please visit https://www.biomedind.com.
The Company is in discussions with potential partners for collaboration on a Phase 3 trial of NA-921, a promising candidate for treatment of diabetic obesity.
The drug is a once-a-day oral capsule based on a novel mechanism of action of GLP-1 and IGF-1 for which the Company has recently filed for patent protection. Its analogue/prodrug has already been approved by the FDA for a certain rare disease, for which the Company is in separate licensing discussions.
"We are actively seeking collaborators to work with us on this exciting new approach for the treatment of Diabetes and Obesity. NA-921 is novel in its approach to targeting both GLP-1 and IGF-1. The drug has shown only minor adverse events in a Phase 2A trial", said Dr, Lloyd Tran, Chairman and CEO of Biomed Industries. He continued "We believe that this new approach will provide a clear choice for patients wanting to have a much more convenient way to take an obesity drug as well as minimize side-effects they experience with current treatments."
More on The Californer
- Women's Everyday Safety Is Changing - The Blue Luna Shows How
- Microgaming Unveils Red Papaya: A New Studio Delivering Cutting-Edge, Feature-Rich Slots
- "Unwrap" This Bad Boy for Christmas - A New Home
- Community Commitment Advances Student Opportunity at Moorpark College
- Rachel Farris, CPA, Founder of Tax Stack AI, Featured in Boss Today on Ethical AI Leadership
About Biomed Industries, Inc.
Biomed Industries™, Inc. is a pioneering bio-pharmaceutical enterprise dedicated to the innovation, development, and commercialization of groundbreaking drug therapeutics addressing unmet medical needs. Biomed stands at the forefront of discovery with its new portfolio of clinical stage drugs targeting Alzheimer's disease, MDD, Rett Syndrome, other neurological challenges, and now Diabetes/Obesity. Additionally, the company is venturing into harnessing AI for drug discovery, enhancing clinical trial procedures, and various other critical domains within the pharmaceutical and medical device sectors.
For further details, please visit https://www.biomedind.com.
Source: Biomed Industries Inc.
Filed Under: Medical
0 Comments
Latest on The Californer
- Milwaukee Job Corps Center Hosts Alumni Day, Calls Alumni to Action on Open Enrollment Campaign
- Connect Promotes Dr. Petra Stegmann as Head of Entrepreneurial Programs
- Xonicwave Expands Premier IT & Cybersecurity Services to San Diego Businesses
- Clean Comedy Kings Debuts At Black Oak Casino Saturday January 3rd
- Golden Paper Identifies Global Growth in Packaging Papers and Upgrades Its High-End Production Capacity
- Car Wash in Northridge CA Stays Open Late Until 10 PM
- Live Performance at the Bal Theater by Angel Sessions
- FASTMAX Launches Modern, AI-Enabled Tax Preparation for Everyday Americans
- CWEHBIT Exchange Expands System Transparency Framework
- AIXEBIT Exchange Launches Compliance Wall to Highlight Global Regulatory Alignment
- Champagne, Caviar Bumps & Pole Performances — Welcome the New Year Early with HandPicked Social Club
- A New Soul Album: Heart Of Kwanzaa, 7-Day Celebration
- Allegiant Management Group Named 2025 Market Leader in Orlando by PropertyManagement.com
- NAFMNP Awarded USDA Cooperative Agreement to Continue MarketLink Program Under FFAB
- Shore Scripts Announces Fall 2025 Short Film Fund Grant Recipients Al Benoit and Ericka Lavin
- California: Governor Newsom launches new initiatives to partner with tech policy experts and accelerate responsible AI in state government
- Costa Oil - 10 Minute Oil Change Surpasses 70 Locations with Construction of San Antonio, TX Stores — Eyes Growth Via Acquisition or Being Acquired
- LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio
- Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
- VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge